Adducin polymorphisms and the treatment of hypertension

Author： Manunta Paolo   Citterio Lorena   Lanzani Chiara   Ferrandi Mara  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.5, 2007-05, pp. : 465-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Adducin and hypertension

By Staessen Jan A   Bianchi Giuseppe  

Pharmacogenomics, Vol. 6, Iss. 7, 2005-10 ,pp. : 665-669

Future Medicine

Access to resources Recommend Favorite

CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension

By Bremer Troy   Man Albert   Kask Kalev   Diamond Cornelius  

Pharmacogenomics, Vol. 7, Iss. 3, 2006-04 ,pp. : 271-279

Future Medicine

Access to resources Recommend Favorite

Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations

By Baudin Bruno  

Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. : 65-73

Future Medicine

Access to resources Recommend Favorite

Telmisartan in the treatment of hypertension

By Rosario Barbara H   Hendra Timothy James  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 4, 2008-04 ,pp. : 485-492

Informa Healthcare

Access to resources Recommend Favorite

Nebivolol: In the Treatment of Hypertension in the US

By Baldwin Claudine M.   Keam Susan J.  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 4, 2009-08 ,pp. : 253-260

Adis International

Access to resources Recommend Favorite